Smith & Nephew plc (LON:SN) has earned a consensus recommendation of “Hold” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, four have given a hold recommendation and four have given a buy recommendation to the company. The average 1-year target price among brokerages that have covered the stock in the last year is GBX 1,396.50 ($18.59).
SN has been the subject of several recent research reports. HSBC upgraded shares of Smith & Nephew to a “buy” rating and upped their price target for the company from GBX 1,320 ($17.57) to GBX 1,530 ($20.37) in a research report on Monday, March 26th. JPMorgan Chase & Co. increased their price objective on shares of Smith & Nephew from GBX 1,411 ($18.79) to GBX 1,463 ($19.48) and gave the stock an “overweight” rating in a research report on Thursday, April 5th. Jefferies Financial Group reiterated a “buy” rating on shares of Smith & Nephew in a research report on Thursday, April 12th. Deutsche Bank reiterated a “hold” rating and set a GBX 1,309.50 ($17.43) price objective (down from GBX 1,315 ($17.51)) on shares of Smith & Nephew in a research report on Tuesday, April 17th. Finally, Credit Suisse Group reiterated a “neutral” rating and set a GBX 1,290 ($17.17) price objective on shares of Smith & Nephew in a research report on Tuesday, April 24th.
LON SN traded down GBX 3.50 ($0.05) on Friday, hitting GBX 1,334.50 ($17.77). The company’s stock had a trading volume of 1,793,279 shares, compared to its average volume of 3,250,000. Smith & Nephew has a 1-year low of GBX 1,173 ($15.62) and a 1-year high of GBX 1,442 ($19.20).
Smith & Nephew Company Profile
Smith & Nephew plc designs, develops, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.